Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus-infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended.
No takes yet. Share an insight, caveat, or question.
Christensen et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: